Wu Yung-Szu, Hsieh Shih-Rong, Wei Hao-Ji, Hsu Chiann-Yi, Tsai Chung-Lin
Department of Cardiovascular Surgery, Cardiovascular Center, Taichung Veterans General Hospital, Taichung.
National Yang-Ming University School of Medicine, Taipei.
Acta Cardiol Sin. 2019 Jul;35(4):387-393. doi: 10.6515/ACS.201907_35(4).20181208A.
The goal of this study was to evaluate the long-term results of coronary artery bypass grafting (CABG) using internal thoracic artery (ITA) grafts in hemodialysis (HD) patients with arteriovenous (AV) fistulae or AV grafts involving the ipsilateral or contralateral brachial artery or radial artery.
From March 2007 to May 2017, 76 end-stage renal disease (ESRD) patients with an upper limb AV fistula or graft for HD underwent CABG at a single center. Group A included 23 patients who underwent CABG using an ITA graft ipsilateral to the AV vascular access (AVVA); Group B included 22 patients who underwent CABG using a contralateral ITA with AVVA; and Group C included 29 patients who underwent CABG with AVVA without the use of an ITA graft. The primary end-point was death from any cause.
The average follow-up period was 34.4 ± 26.9 months. Death from any cause occurred in 6 (26.09%) patients in Group A, 8 (36.36%) patients in Group B, and 17 (58.62%) patients in Group C (log-rank p = 0.04). There was no significant difference in death rate between Groups A and B. The risk of death was lower in the patients with CABG using an ITA graft (ITA CABG) compared to the patients without ITA CABG [HR 0.41 (95% CI, 0.20-0.84), p = 0.015].
The HD patients who underwent CABG with an ipsilateral location of the ITA and AVVA did not have an increased risk of death compared to the patients who underwent CABG with a contralateral location of the ITA and AVVA. In addition, the use of ITA in CABG resulted in better outcomes in the HD patients.
本研究的目的是评估在患有动静脉(AV)内瘘或涉及同侧或对侧肱动脉或桡动脉的AV移植物的血液透析(HD)患者中,使用胸廓内动脉(ITA)移植物进行冠状动脉旁路移植术(CABG)的长期结果。
2007年3月至2017年5月,76例患有上肢AV内瘘或用于HD的移植物的终末期肾病(ESRD)患者在单一中心接受了CABG。A组包括23例使用与AV血管通路(AVVA)同侧的ITA移植物进行CABG的患者;B组包括22例使用与AVVA对侧的ITA进行CABG的患者;C组包括29例在有AVVA的情况下未使用ITA移植物进行CABG的患者。主要终点是任何原因导致的死亡。
平均随访期为34.4±26.9个月。A组6例(26.09%)患者、B组8例(36.36%)患者和C组17例(58.62%)患者发生了任何原因导致的死亡(对数秩检验p=0.04)。A组和B组之间的死亡率没有显著差异。与未使用ITA进行CABG的患者相比,使用ITA移植物进行CABG的患者死亡风险更低[风险比0.41(95%置信区间,0.20-0.84),p=0.015]。
与使用ITA和AVVA对侧位置进行CABG的患者相比,使用ITA和AVVA同侧位置进行CABG的HD患者死亡风险没有增加。此外,在CABG中使用ITA可使HD患者获得更好的结果。